Extended Data Fig. 2: Effect of alterations in cell cycle regulators on EAC survival.
A. Kaplan-Meier survival curves of patients with EAC with wild type CDKN2A compared to those with heterozygous loss of CDKN2A. Heterozygous deletions could be inferred only in n = 779 patients with EAC with WGS or WES data. Kaplan-Meier survival curves of patients with EAC with alterations in CCND1 (p-value = 0.01) (B), TP53 (C), CDKN1A (D), CCNE1 (E) and MDM2 (F) compared to the corresponding wild type samples. Survival curves B-F were done using the whole cohort of 1032 EACs. GoF, gain-of-function; LoF, loss-of-function; EAC, esophageal adenocarcinoma; Het, Heterozygous deletions. Log-rank method was used to estimate the p-values.
